Targeting Mitochondria Metabolisms for Novel AML Therapy Development

Simple item page
dc.contributor.advisorKirienko, Natasha V.en_US
dc.contributor.advisorCarson, Danielen_US
dc.creatorPei, Jingqien_US
dc.date.accessioned2021-12-06T19:48:25Zen_US
dc.date.available2021-12-06T19:48:25Zen_US
dc.date.created2021-12en_US
dc.date.issued2021-12-03en_US
dc.date.submittedDecember 2021en_US
dc.date.updated2021-12-06T19:48:25Zen_US
dc.description.abstractMitochondrial dysfunction contributes to a wide variety of pathologies, including neurodegenerative diseases, cancer, metabolic diseases, and aging. As a consequence, oncogenesis and tumor progression heavily depends on the mitochondrial metabolism. I investigated the potential of using mitochondrial targeting drugs to selectively remove leukemia, a type of cancer that has been previously identified to be sensitive to mitochondria-targeting drugs. I optimized Hoeschst/PI dual-staining assay for quick, high-throughput screening of leukemia cell’ viability under mitochondria-targeting drugs treatments. Through combination of mitochondria-targeting drugs and anti-cancer chemotherapeutic agents, I observed high synergistic effect in the removal of leukemia in these combinations. I characterized several changes in mitochondria bioenergetic parameters that are correlated with the sensitivity of mitochondria-targeting drug to leukemia. These observations also applied to primary AML samples extracted from patients. Mitochondria health is actively surveilled by several different systems to ensure the preservation of cellular viability. Mitophagy is a conservative process that removes superfluous or damaged mitochondria. I identified 8 compounds with mitophagy activation effect that can stabilize PINK-1/PINK1 in C. elegans with my colleague Dr. Elissa Tjahjono. I observed these compounds induced selective removal of leukemia alone or in combination with other anti-cancer chemotherapeutic agents. Furthermore, these compounds reduced paralysis level in C. elegans model of neurodegenerative diseases. Taken together, activation of mitophagy using these compounds may be a novel method to develop selective therapy for leukemia and neurodegenerative diseases.en_US
dc.format.mimetypeapplication/pdfen_US
dc.identifier.citationPei, Jingqi. "Targeting Mitochondria Metabolisms for Novel AML Therapy Development." (2021) Diss., Rice University. <a href="https://hdl.handle.net/1911/111750">https://hdl.handle.net/1911/111750</a>.en_US
dc.identifier.urihttps://hdl.handle.net/1911/111750en_US
dc.language.isoengen_US
dc.rightsCopyright is held by the author, unless otherwise indicated. Permission to reuse, publish, or reproduce the work beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.en_US
dc.subjectAMLen_US
dc.subjectLeukemiaen_US
dc.subjectMitochondriaen_US
dc.subjectMitocanen_US
dc.subjectMitophagyen_US
dc.subjectSynergyen_US
dc.subjectPINK1en_US
dc.titleTargeting Mitochondria Metabolisms for Novel AML Therapy Developmenten_US
dc.typeThesisen_US
dc.type.materialTexten_US
thesis.degree.departmentBiochemistry and Cell Biologyen_US
thesis.degree.disciplineNatural Sciencesen_US
thesis.degree.grantorRice Universityen_US
thesis.degree.levelDoctoralen_US
thesis.degree.nameDoctor of Philosophyen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PEI-DOCUMENT-2021.pdf
Size:
33.1 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
5.84 KB
Format:
Plain Text
Description:
Download
No Thumbnail Available
Name:
LICENSE.txt
Size:
2.6 KB
Format:
Plain Text
Description:
Download
Collections
Rice University Theses and Dissertations